發(fā)布時(shí)間：2018-04-19 01:09

  本文選題：伊立替康 + 替吉奧��； 參考：《中國藥房》2017年11期

【摘要】：目的:觀察伊立替康聯(lián)合替吉奧、雷替曲塞或氟尿嘧啶治療進(jìn)展期胃癌的臨床療效和安全性。方法:選取2013年5月—2016年5月我院收治的一線方案治療失敗的進(jìn)展期胃癌患者100例為研究對(duì)象。按照隨機(jī)數(shù)字表法分為觀察組(n=32)、對(duì)照A組(n=33)和對(duì)照B組(n=35)。觀察組患者給予鹽酸伊立替康注射液180 mg/m2,ivgtt(d1)+替吉奧膠囊60 mg/m2,po,bid(餐后)治療,2周為1個(gè)周期;對(duì)照A組患者給予鹽酸伊立替康注射液180 mg/m2,ivgtt(d1)+注射用雷替曲塞3 mg/m2,ivgtt(d1,15 min),3周為1個(gè)周期;對(duì)照B組患者給予鹽酸伊立替康注射液180 mg/m2,ivgtt(d1)+亞葉酸鈣注射液200 mg/m2,ivgtt(d1)+氟尿嘧啶注射液400 mg/m2,iv+2 400~3 000 mg/m2,ivgtt(46 h),d1,2周為1個(gè)周期。觀察組和對(duì)照A組患者均治療2個(gè)周期,之后第7天進(jìn)行療效評(píng)價(jià);對(duì)照B組患者治療3個(gè)周期,之后第12天進(jìn)行療效評(píng)價(jià)。觀察3組患者臨床療效和不良反應(yīng)發(fā)生情況。結(jié)果:對(duì)照A組患者脫落1例,對(duì)照B組患者脫落2例,最終納入統(tǒng)計(jì)的合格病例數(shù)為97例,其中觀察組32例、對(duì)照A組32例、對(duì)照B組33例。觀察組患者的總緩解率(53.13%)明顯高于對(duì)照A組(43.75%)和對(duì)照B組(36.36%),觀察組患者的總控制率(81.25%)明顯高于對(duì)照A組(68.75%)和對(duì)照B組(57.58%),差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。3組患者不良反應(yīng)發(fā)生率比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:伊立替康聯(lián)合替吉奧治療進(jìn)展期胃癌患者的臨床療效較伊立替康聯(lián)合雷替曲塞或氟尿嘧啶更好,且安全性較好。
[Abstract]:Aim: to observe the clinical efficacy and safety of irinotecan combined with tetigol, retitrexed or fluorouracil in the treatment of advanced gastric cancer.Methods: from May 2013 to May 2016, 100 patients with advanced gastric cancer who failed in first-line treatment were selected.According to the method of random number table, the observation group was divided into two groups: observation group (n = 32), control group A (n = 35) and control group B (n = 35).The patients in the observation group were treated with Ilytecan Hydrochloride injection 180 mg / m 2 iv / d 1) tigeo capsule 60 mg / m 2 pobido (postprandial) was treated for 2 weeks, and the control group A group was treated with the injection 180 mg / m 2 / d iv gttd1) for a period of 3 mg / m 2 iv gtttd1 / 15 min for a period of 15 min. The patients in the control group were treated with Irititecan Hydrochloride injection 180 mg / m 2 / d iv gttd1) for 3 weeks, and the control group was given the injection of Ilytecan Hydrochloride 180 mg / m 2 / d iv gttd1 for 15 min.In control group B, patients were given Ilitecan Hydrochloride 180 mg / m2 iv / d 1) calcium folate injection 200 mg / m 2 iv iv 2 400 mg / m 2 / d 2 iv 2 400 mg / m 2 / d 1.Observation group and control group A patients were treated for 2 cycles, and then 7 days to evaluate the efficacy, control group B patients treated for 3 cycles, then 12 days to evaluate the efficacy.The clinical efficacy and adverse reactions were observed in three groups.Results: there were 1 case in control group A and 2 cases in control group B. 97 eligible cases were included in the statistics, including 32 cases in observation group, 32 cases in control group A and 33 cases in control group B.The total remission rate of observation group (53.13) was significantly higher than that of control group A (43.75) and control group B (36.36%), and the total control rate of observation group (81.25) was significantly higher than that of control group A (68.75%) and control group B (57.58%).The difference was not statistically significant (P 0.05).Conclusion: the clinical efficacy of irinotecan combined with tigualone in the treatment of advanced gastric cancer is better than that of irinotecan combined with retitrexil or fluorouracil, and the safety is better than that of irinotecan combined with rititrexide or fluorouracil.
【作者單位】： 安陽市第六人民醫(yī)院普外科;
【分類號(hào)】：R735.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 武陽;;伊立替康單藥與聯(lián)合消癌平治療老年晚期胃癌的比較研究[J];中國藥房;2016年05期

2 周寧;周洋;唐勇;;曲妥珠單抗聯(lián)合紫杉醇+替吉奧二線治療HER-2陽性轉(zhuǎn)移性晚期胃癌的療效[J];中國腫瘤生物治療雜志;2016年01期

3 胥敏;;奧沙利鉑聯(lián)合替吉奧或卡培他濱方案用于胃癌術(shù)后療效對(duì)比[J];中國藥業(yè);2016年01期

4 賈曉瓊;溫珍平;孫秋穎;;替吉奧聯(lián)合伊立替康二線治療進(jìn)展期胃癌療效觀察[J];內(nèi)蒙古醫(yī)學(xué)雜志;2015年12期

5 孟威;;西妥昔單抗聯(lián)合5-氟尿嘧啶和伊立替康治療HER2陽性晚期胃癌的臨床研究[J];中國中西醫(yī)結(jié)合消化雜志;2015年10期

6 劉文靜;趙艷秋;胡秀峰;吳紅波;陳利娟;吳慧娟;王居峰;;紫杉醇脂質(zhì)體聯(lián)合替吉奧治療晚期胃癌的有效性及安全性評(píng)價(jià)[J];鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2014年06期

7 崔勇霞;羅執(zhí)芬;盧創(chuàng)新;周建煒;馬寧;周云;;伊立替康聯(lián)合替吉奧或5-氟尿嘧啶方案二線治療晚期胃癌的療效觀察[J];腫瘤防治研究;2014年07期

8 卜麗佳;張逸寅;熊福星;郝吉慶;;伊立替康或奧沙利鉑聯(lián)合氟尿嘧啶類藥物一線治療晚期胃癌的療效觀察[J];安徽醫(yī)科大學(xué)學(xué)報(bào);2013年11期

9 陳育苗;;奧沙利鉑、伊立替康聯(lián)合5-氟尿嘧啶、亞葉酸治療轉(zhuǎn)移或復(fù)發(fā)胃癌的臨床療效及不良反應(yīng)觀察[J];胃腸病學(xué)和肝病學(xué)雜志;2013年09期

10 笪潔;杜瀛瀛;;伊立替康聯(lián)合替吉奧三線治療進(jìn)展期胃癌臨床觀察[J];安徽醫(yī)藥;2012年12期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 宋振國;何振;張斌;;奧沙利鉑聯(lián)合替吉奧治療晚期胃癌的效果分析[J];臨床醫(yī)學(xué)工程;2017年06期

2 魯穎;張磊;;奧沙利鉑及替吉奧聯(lián)合護(hù)理干預(yù)治療胃癌臨床評(píng)價(jià)[J];中國藥業(yè);2017年11期

3 梁淑影;王峰;王s，

本文編號(hào)：1770898